Engineering M13 bacteriophage platforms for cancer therapy applications

Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2015. === Cataloged from PDF version of thesis. === Includes bibliographical references (pages 46-48). === Two novel schemes for engineering M13 bacteriophage for application in the diagnosis, imaging and trea...

Full description

Bibliographic Details
Main Author: Tsedev, Uyanga
Other Authors: Angela M. Belcher and Alan J. Grodzinsky.
Format: Others
Language:English
Published: Massachusetts Institute of Technology 2016
Subjects:
Online Access:http://hdl.handle.net/1721.1/103838
id ndltd-MIT-oai-dspace.mit.edu-1721.1-103838
record_format oai_dc
spelling ndltd-MIT-oai-dspace.mit.edu-1721.1-1038382019-05-02T15:39:16Z Engineering M13 bacteriophage platforms for cancer therapy applications Tsedev, Uyanga Angela M. Belcher and Alan J. Grodzinsky. Massachusetts Institute of Technology. Department of Mechanical Engineering. Massachusetts Institute of Technology. Department of Mechanical Engineering. Mechanical Engineering. Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2015. Cataloged from PDF version of thesis. Includes bibliographical references (pages 46-48). Two novel schemes for engineering M13 bacteriophage for application in the diagnosis, imaging and treatment of human tumors are proposed. Firstly, by exploiting the uniquely malleable biology of the M13 filamentous phage, we have engineered filamentous phages of shorter lengths by constructing our own set of small viral ssDNA that are packaged by M13 capsid proteins. These 'inho' phages can be sized to ~50nm and above in length. The small phage retains the M13 major and minor coat proteins which have previously been manipulated to serve as tethers to carry various therapy and imaging agents and target specific cancer sites. Now with the ability to control the aspect ratio of these rigid, rod-like phages we can further improve on M13 based cancer detection by optimizing for phage blood circulation and tumor extravasation. Secondly, we have added to our cancer targeting M13 platform collection by cloning for chlorotoxin display on the tail p3 capsid protein of M13. Chlorotoxin can induce passage across blood-brain barrier, targets for cancer cells, and specifically internalizes to glioma cells. Expression of chlorotoxin on M13 will allow us to capitalize on its strong affinity for tumors of neuroectodermal origin and expand the M13 therapy and imaging platform to tumor masses in the brain. by Uyanga Tsedev. S.M. 2016-08-02T20:07:16Z 2016-08-02T20:07:16Z 2015 2015 Thesis http://hdl.handle.net/1721.1/103838 953868616 eng M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 48 pages application/pdf Massachusetts Institute of Technology
collection NDLTD
language English
format Others
sources NDLTD
topic Mechanical Engineering.
spellingShingle Mechanical Engineering.
Tsedev, Uyanga
Engineering M13 bacteriophage platforms for cancer therapy applications
description Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2015. === Cataloged from PDF version of thesis. === Includes bibliographical references (pages 46-48). === Two novel schemes for engineering M13 bacteriophage for application in the diagnosis, imaging and treatment of human tumors are proposed. Firstly, by exploiting the uniquely malleable biology of the M13 filamentous phage, we have engineered filamentous phages of shorter lengths by constructing our own set of small viral ssDNA that are packaged by M13 capsid proteins. These 'inho' phages can be sized to ~50nm and above in length. The small phage retains the M13 major and minor coat proteins which have previously been manipulated to serve as tethers to carry various therapy and imaging agents and target specific cancer sites. Now with the ability to control the aspect ratio of these rigid, rod-like phages we can further improve on M13 based cancer detection by optimizing for phage blood circulation and tumor extravasation. Secondly, we have added to our cancer targeting M13 platform collection by cloning for chlorotoxin display on the tail p3 capsid protein of M13. Chlorotoxin can induce passage across blood-brain barrier, targets for cancer cells, and specifically internalizes to glioma cells. Expression of chlorotoxin on M13 will allow us to capitalize on its strong affinity for tumors of neuroectodermal origin and expand the M13 therapy and imaging platform to tumor masses in the brain. === by Uyanga Tsedev. === S.M.
author2 Angela M. Belcher and Alan J. Grodzinsky.
author_facet Angela M. Belcher and Alan J. Grodzinsky.
Tsedev, Uyanga
author Tsedev, Uyanga
author_sort Tsedev, Uyanga
title Engineering M13 bacteriophage platforms for cancer therapy applications
title_short Engineering M13 bacteriophage platforms for cancer therapy applications
title_full Engineering M13 bacteriophage platforms for cancer therapy applications
title_fullStr Engineering M13 bacteriophage platforms for cancer therapy applications
title_full_unstemmed Engineering M13 bacteriophage platforms for cancer therapy applications
title_sort engineering m13 bacteriophage platforms for cancer therapy applications
publisher Massachusetts Institute of Technology
publishDate 2016
url http://hdl.handle.net/1721.1/103838
work_keys_str_mv AT tsedevuyanga engineeringm13bacteriophageplatformsforcancertherapyapplications
_version_ 1719025366854533120